NEWSROOM
News & Stories
Newsroom
Press Releases
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis Read More
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to fuel breast cancer research and produce practice-changing results All six presentations will emphasize how MammaPrint® and BluePrint® empower personalized, proactive treatment decisions with test results Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrint® Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendia’s growing global footprint in breast cancer to inform Read More








